{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:10:11Z","timestamp":1792678211600,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.autrev.2015.02.002","type":"journal-article","created":{"date-parts":[[2015,2,21]],"date-time":"2015-02-21T02:15:12Z","timestamp":1424484912000},"page":"575-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?"],"prefix":"10.1016","volume":"14","author":[{"given":"Michele","family":"Iudici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Moroncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2015.02.002_bb0005","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.02.002_bb0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.02.002_bb0015","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.autrev.2014.08.029","article-title":"Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature","volume":"13","author":"Ferri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.02.002_bb0020","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972\u20132002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2015.02.002_bb0025","article-title":"Pulmonary complications: one of the most challenging complications of systemic sclerosis","volume":"48","author":"Wells","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.02.002_bb0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.autrev.2015.02.002_bb0035","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1148\/radiology.176.3.2389033","article-title":"Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography","volume":"176","author":"Schurawitzki","year":"1990","journal-title":"Radiology"},{"key":"10.1016\/j.autrev.2015.02.002_bb0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrrheum.2014.149","article-title":"Interstitial lung disease in connective tissue disease-mechanisms and management","volume":"10","author":"Wells","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2015.02.002_bb0045","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.02.002_bb0050","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.02.002_bb0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00408-013-9532-y","article-title":"Treating CTDs related fibrotic ILDs by immunosuppressants: \u201cfacts and faults\u201d","volume":"192","author":"Papiris","year":"2014","journal-title":"Lung"},{"key":"10.1016\/j.autrev.2015.02.002_bb0060","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.02.002_bb0065","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.02.002_bb0070","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2015.02.002_bb0075","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.autrev.2011.04.025","article-title":"Systemic sclerosis refractory disease: from the skin to the heart","volume":"10","author":"Almeida","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.02.002_bb0080","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/art.38702","article-title":"Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis. How similar and distinct?","volume":"66","author":"Herzog","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2015.02.002_bb0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/art.1780310207","article-title":"Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis","volume":"31","author":"Steen","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.02.002_bb0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0140-6736(91)91235-M","article-title":"Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis","volume":"338","author":"Briggs","year":"1991","journal-title":"Briggs Lancet"},{"key":"10.1016\/j.autrev.2015.02.002_bb0095","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.114.3.801","article-title":"African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease","volume":"114","author":"Greidinger","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2015.02.002_bb0100","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2015.02.002_bb0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease","volume":"52","author":"Moore","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.02.002_bb0110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.02.002_bb0115","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2015.02.002_bb0120","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.22099","article-title":"Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline","volume":"55","author":"Plastiras","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.02.002_bb0125","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2015.02.002_bb0130","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/art.22696","article-title":"Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression","volume":"56","author":"Goh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.02.002_bb0135","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2015.02.002_bb0140","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1378\/chest.08-0053","article-title":"Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival","volume":"134","author":"Fischer","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2015.02.002_bb0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.02.002_bb0150","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.200403-331OC","article-title":"Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia","volume":"171","author":"Jegal","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2015.02.002_bb0155","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2174\/157339710791330768","article-title":"Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design","volume":"6","author":"Khanna","year":"2010","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.autrev.2015.02.002_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2014-206076","article-title":"Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis","author":"Tashkin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.02.002_bb0165","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/art.30467","article-title":"Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.02.002_bb0170","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.02.002_bb0175","doi-asserted-by":"crossref","first-page":"R124","DOI":"10.1186\/ar2534","article-title":"Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies","volume":"10","author":"Nannini","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.02.002_bb0180","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00296-011-1967-y","article-title":"Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis","volume":"32","author":"Poormoghim","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2015.02.002_bb0185","first-page":"731","article-title":"Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis","volume":"29","author":"Giacomelli","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.02.002_bb0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/ar2576","article-title":"Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario","volume":"11","author":"Miniati","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.02.002_bb0195","first-page":"838","article-title":"Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease","volume":"20","author":"Silver","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.02.002_bb0200","article-title":"Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders","author":"Iudici","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.02.002_bb0205","doi-asserted-by":"crossref","first-page":"143637","DOI":"10.1155\/2012\/143637","article-title":"Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis","volume":"2012","author":"Tzouvelekis","year":"2012","journal-title":"Pulm Med"},{"key":"10.1016\/j.autrev.2015.02.002_bb0210","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","article-title":"Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study","volume":"191","author":"Panopoulos","year":"2013","journal-title":"Lung"},{"key":"10.1016\/j.autrev.2015.02.002_bb0215","unstructured":"clinicaltrials.gov\/ct2\/show\/NCT00883129."},{"issue":"Suppl. 71","key":"10.1016\/j.autrev.2015.02.002_bb0220","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2015.02.002_bb0225","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","author":"Bosello","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.02.002_bb0230","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","author":"Jordan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.02.002_bb0235","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/art.30548","article-title":"A one-year, phase I\/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"311","key":"10.1016\/j.autrev.2015.02.002_bb0240","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"25","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2015.02.002_bb0245","first-page":"1064","article-title":"Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study","volume":"35","author":"Berezne","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.02.002_bb0250","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","article-title":"Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2014a consensus of systemic sclerosis experts","volume":"42","author":"Walker","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.02.002_bb0255","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/resp.12214","article-title":"Rituximab in severe, treatment-refractory interstitial lung disease","volume":"19","author":"Keir","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.autrev.2015.02.002_bb0260","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.02.002_bb0265","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/01.bor.0000434670.39773.a8","article-title":"Lung transplantation in patients with scleroderma","volume":"25","author":"De Cruz","year":"2013","journal-title":"Curr Opin Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721500035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721500035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:26:28Z","timestamp":1537835188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899721500035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S156899721500035X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2015.02.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2015.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}